|
Jan 12
|
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
|
|
Jan 11
|
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
|
|
Jan 11
|
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
|
|
Jan 10
|
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
|
|
Nov 23
|
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
|
|
Oct 19
|
Here's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
|
|
Oct 16
|
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
|
|
Aug 8
|
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
|
|
May 22
|
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease
|